TABLE 30Haematological response to dasatinib in CML-BC: summary

StudyLength of follow-upDoseSubgroupIMFCompleteMajorMinorNELOverall
Talpaz et al. (2006)104> 12 monthsa,bMixed/NRLBCMixed7/10 = 70.0%8/10 = 80.0%0/10 = 00.0%1/10 = 10.0%
MBCMixed8/23 = 34.8%14/23 = 60.9%4/23 = 17.4%6/23 = 26.1%
Cortes et al. (2007)3817 monthsaMixed/NRMixed4/10 = 40.0%6/10 = 60.0%
Cortes et al. (2007)138 monthsc70 mg b.i.d.LBCMixed11/42 = 26.2%13/42 = 31.0%2/42 = 04.8%2/42 = 04.8%15/42 = 35.7%
MBCMixed19/74 = 25.7%25/74 = 33.8%14/74 = 18.9%6/74 = 08.1%39/74 = 52.7%
12 monthsc,d70 mg b.i.d.ImILBC33%e
MBC20%e
ImRLBC36%e
MBC35%e

IMF, imatinib failure status; NEL, no evidence of leukaemia; NR, not reported.

a

Median follow-up.

b

Abstract states median follow up ‘more than 12 months’, but precise data not given in text.

c

Minimum follow-up.

d

Data extracted from conference abstract presenting updated results.121

e

Percentages only reported in text; unclear what size of population with expanded enrolment is.

From: 2, Assessment of clinical effectiveness

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.